Elsevier

Journal of Hepatology

Volume 15, Issue 3, July 1992, Pages 336-344
Journal of Hepatology

Regular paper
A controlled trial of prednisolone treatment in primary biliary cirrhosis: Three-year results

https://doi.org/10.1016/0168-8278(92)90065-WGet rights and content

Abstract

The results of a 3-year, placebo-controlled trial of prednisolone treatment in primary biliary cirrhosis (PBC) are presented. The active (n = 19) and placebo (n = 17) arms were initially well matched for age, menopausal status and disease severity. At 3 years hepatic symptoms were relatively improved in the prednisolone group. Hepatic mortality was 319 (prednisolone), 517 (placebo) (p = n.s.). For all liver blood tests the trend favoured prednisolone treatment, though the differences were only significant for alkaline phosphatase and protein. All immunoglobulins fell significantly. Quantitative ELISA determination of antimitochondrial antibody showed a significant fall in the prednisolone group compared with placebo (p < 0.001 at 1 year, p < 0.05 at 3 years). Deterioration in histology (appearance of cirrhosis) was more common in the placebo group. Overall hepatic function (hepatic mortality, doubling in bilirubin, 6 g/l fall in albumin, de novo appearance of cirrhosis or symptoms of portal hypertension) was significantly worse in the placebo group (p < 0.01). After 3 years no significant differences could be detected in bone mineral content (single photon absorptiometry of radius and femur) between the two groups or in comparison with other PBC patients. Thus, after 3 years, prednisolone treatment was associated with a better overall hepatic outcome and little evidence of increased bone loss.

References (20)

There are more references available in the full text version of this article.

Cited by (179)

  • Bile Duct Diseases

    2023, MacSween's Pathology of the Liver, Eighth Edition
  • The challenges of primary biliary cholangitis: What is new and what needs to be done

    2019, Journal of Autoimmunity
    Citation Excerpt :

    Notably, mycophenolate mofetil exposure, in addition to tacrolimus, was associated with higher PBC post-LT recurrence rate in a recent large international study [107]. Although steroids are not recommended in PBC because of their side effects, there is some evidence that they may be of benefit in selected patients [255,256]. There are no data on the role of steroids in post-LT recurrence.

  • Bile Duct Diseases

    2018, MacSween's Pathology of the Liver
  • Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management

    2015, Clinical Gastroenterology and Hepatology
  • Cholestatic liver disease

    2014, Medical Clinics of North America
View all citing articles on Scopus
View full text